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Abnormal elevation of amyloid β-peptide (Aβ) levels in the brain is the primary trigger
for neuronal cell death specific to Alzheimer’s disease (AD). It is now evident that Aβ
levels in the brain are manipulable due to a dynamic equilibrium between its production
from the amyloid precursor protein (APP) and removal by amyloid clearance proteins.
Clearance can be either enzymic or non-enzymic (binding/transport proteins). Intriguingly
several of the main amyloid-degrading enzymes (ADEs) are members of the M13 peptidase
family (neprilysin (NEP), NEP2 and the endothelin converting enzymes (ECE-1 and -2)).
A distinct metallopeptidase, insulin-degrading enzyme (IDE), also contributes to Aβ
degradation in the brain. The ADE family currently embraces more than 20 members, both
membrane-bound and soluble, and of differing cellular locations. NEP plays an important
role in brain function terminating neuropeptide signals. Its decrease in specific brain areas
with age or after hypoxia, ischaemia or stroke contribute significantly to the development
of AD pathology. The recently discovered mechanism of epigenetic regulation of NEP (and
other genes) by the APP intracellular domain (AICD) and its dependence on the cell type
and APP isoform expression suggest possibilities for selective manipulation of NEP gene
expression in neuronal cells. We have also observed that another amyloid-clearing protein,
namely transthyretin (TTR), is also regulated in the neuronal cell by a mechanism similar
to NEP. Dependence of amyloid clearance proteins on histone deacetylases and the ability
of HDAC inhibitors to up-regulate their expression in the brain opens new avenues for
developing preventive strategies in AD.
Keywords: amyloid peptide, APP, AICD, endothelin-converting enzyme, histone deacetylases, insulin-degrading
enzyme, neprilysin, transthyretin
INTRODUCTION
Overproduction and accumulation in the brain of abnormally
high concentrations of the amyloid-β (Aβ) peptide and its
oligomers causing synaptic loss and neuronal cell death are con-
sidered among the principal pathological events underlying neu-
rodegeneration and Alzheimer’s disease (AD; Hardy and Higgins,
1992; Walsh et al., 2002; Hardy, 2009). Aβ is produced by the
sequential proteolytic cleavage of the membrane-bound amyloid
precursor protein (APP) by an aspartic protease, β-secretase
(BACE1), followed by the presenilin-dependent γ-secretase (for
details see Figure 1). Under normal physiological conditions
it has important neuronal functions including transcriptional
regulation (Koudinov and Berezov, 2004; Barucker et al., 2014).
However, in some individuals mutations in the APP gene, or in the
Abbreviations: Aβ, amyloid β-peptide; AD, Alzheimer’s disease; AICD, APP
intracellular domain; APLP, APP-like protein; APP, amyloid precursor pro-
tein; ECE, endothelin-converting enzyme; IDE, insulin-degrading enzyme;
HDAC, histone deacetylase; NEP, neprilysin; PKC, protein kinase C; TTR,
transthyretin; VA, valproic acid.
presenilin genes (PS1 and PS2), cause an increase in relative abun-
dance of Aβ42 and development of AD pathology at a relatively
early age. Our understanding of the molecular mechanisms of AD
pathology to date derive from studies of the families manifesting
early-onset AD and from studying transgenic animals expressing
human genes bearing these pathological mutations (Guerreiro
et al., 2012; LaFerla and Green, 2012). However, all attempts to
create an effective drug against AD pathology based exclusively
on the amyloid cascade hypothesis have not been fruitful. This
can be explained by the fact that the majority of AD cases are of
the late-onset, sporadic form not linked to mutations of the major
AD-related genes but caused by some other pathological changes
in normal brain physiology which predispose to overproduction
and accumulation of Aβ in the brain over the years. Among
them are neuroinflammation, poor diet, toxic environment, brain
trauma, hypoxia, stroke and mutations in a number of other neu-
ronal genes which not only shift the whole neuronal metabolism
towards accumulation of Aβ (Karch et al., 2012) but also affect its
intrinsic clearance both via transport and perfusion mechanisms
or proteolytic cleavage.
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FIGURE 1 | Schematic representation of Aβ production and removal
from the brain. The proteolytic processing of the large, transmembrane,
APP occurs in two distinct amyloidogenic and non-amyloidogenic
pathways. The amyloidogenic pathway involves the sequential cleavage of
APP by an aspartic proteinase, β-secretase, which releases a soluble
ectodomain (sAPPβ) and the C-terminal fragment CTF99. This, in turn, is
cleaved by another aspartic proteinase, γ-secretase, generating the
transcriptional regulator APP intracellular domain (AICD), and releasing
the 39-42 amino acid amyloid-β peptide (Aβ). Due to its very high ability
for aggregation, Aβ forms dimers, trimers and higher level oligomers
which are toxic to cells and cause neuronal death. Formation of amyloid
plaques from Aβ aggregates in complex with other proteins is a hallmark
of AD but is considered as a scavenging process. In the
non-amyloidogenic pathway APP molecules are cleaved at the
α-secretase site within the Aβ-domain releasing a soluble ectodomain
sAPPα and the C-terminal fragment CTF83. Proteolytic cleavage of CTF83
by γ-secretase releases AICD and p3 fragment whose functions are still
unknown. The AICD fragment produced in the amyloidogenic pathway
binds to a stabilizing factor Fe65 and in a complex with other factors (the
histone acetyl transferase, Tip60, and a Mediator complex subunit
Med12) can act as a transcription enhancer regulating expression of a
variety of genes, including the Aβ-degrading enzyme neprilysin and
clearance protein transthyretin (TTR). This process was found to be
specific to the neuronal APP695 isoform. AICD produced in the
non-amyloidogenic pathway and from other APP isoforms (APP751 and
APP770) is most likely degraded (by some intracellular proteases, e.g.,
insulin-degrading enzyme and caspases). Soluble APP ectodomains,
sAPPα and sAPPβ, have been shown to have neuroprotective properties.
It is now becoming more evident that Aβ levels in the
brain are manipulable due to a dynamic equilibrium between
its production from APP and removal by a cohort of amyloid
clearance proteins which can be either of enzymic nature (pro-
teases) or non-enzymic (binding/transport proteins) (Figure 1).
The number of enzymes capable of proteolytic degradation of Aβ
discovered to date is rapidly growing and currently the family
of amyloid-degrading enzymes (ADEs) embrace more than 20
members both membrane-bound and soluble, and of differ-
ing cellular and subcellular locations (for review see Marr and
Spencer, 2010; Nalivaeva et al., 2012a,c; Grimm et al., 2013;
Pacheco-Quinto et al., 2013). Intriguingly several of the main
ADEs are members of the M13 peptidase family (neprilysin
(NEP), NEP2 and endothelin converting enzymes (ECE-1 and
ECE-2)). Another metallopeptidase from the M16 family, insulin-
degrading enzyme (IDE), also plays a significant role in Aβ
degradation in the brain (Leissring et al., 2003; Qiu and Folstein,
2006). All these enzymes have been mostly studied in recent years
with regard to their role in AD pathology or as therapeutic targets.
This review will focus on the mechanisms regulating expression of
their genes in vivo and vitro.
The amyloid binding/transport proteins which interact with
Aβ and modulate its solubility, transport, clearance, degradation,
and fibril formation are now widely studied. The serum amyloid
P component (SAP), as well as apolipoprotein J (clusterin), have
been described as the main Aβ-binding proteins while various
apolipoproteins (apoA-IV, apoE, and apoA-I), as well as albu-
min (HSA) and fibulin were identified as minor contributors
(Calero et al., 2012; Yu and Tan, 2012). Despite being a minor
contributor to Aβ-binding in the plasma, apoE (especially the
apoE4) is considered as one of the major contributors to Aβ
clearance in the brain and is the major genetic risk factor for
development of late-onset AD (for review see Hauser and Ryan,
2013). It has been suggested the ApoE/LRP1-mediated clearance
of Aβ across the blood brain barrier (BBB) is the key event in
the regulation of Aβ transport from brain to periphery which
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suggests that direct targeting of this process at the BBB could have
potential in the treatment of late-onset AD (Martiskainen et al.,
2013).
Another group of transport proteins, namely the ATP-binding
cassette (ABC) transporters, which are localized on the surface
of brain endothelial cells of the BBB and brain parenchyma,
also contribute to Aβ clearance. Among these transporters the
most important role in Aβ binding and transport is ascribed to
ABCB1 (P-glycoprotein, P-gp), ABCG2 (breast cancer resistant
protein, BCRP), ABCC1 (multidrug resistance protein 1, MRP1),
and the cholesterol transporter ABCA (Abuznait and Kaddoumi,
2012). Recently special attention has been paid to transthyretin
(TTR, formely known as thyroxine binding prealbumin) which
can suppress the AD phenotype in transgenic animal models
and reduce cerebral Aβ deposition (Li et al., 2013). Although
being amyloidogenic itself in peripheral tissues, in the brain
it was shown to have an anti-Aβ-amyloidogenic effect and is
considered to have potential therapeutic value (Buxbaum and
Reixach, 2009). In the brain this protein is mainly expressed
by the cells of choroid plexus (Sousa et al., 2007) but can also
be detected and regulated in neuronal cells (Kerridge et al.,
2014) and apart from the transport function it can contribute to
regulation of important neuronal proteins e.g., 14-3-3ζ protein
and neuropeptide Y (Nunes et al., 2006; Vieira and Saraiva,
2013) and brain functions, including memory (Brouillette and
Quirion, 2008; Vieira and Saraiva, 2014). TTR has been one of
the proteins of interest in our recent research and the mecha-
nisms of its epigenetic regulation were shown to be similar to
those of an amyloid-degrading peptidase, NEP (Kerridge et al.,
2014). Recent data also suggest that TTR expression in neu-
ronal cells is regulated by heat shock factor 1 (HSF1) which
is the major regulator of cellular stress responses (Wang et al.,
2014a).
Within neuronal cells abnormal accumulation of Aβ might
also result from the impairment of the two major protein quality
control systems providing clearance of misfolded, aggregated or
long-lived proteins and represented by autophagy-lysosome and
ubiquitin-proteasome systems (for review see Lee et al., 2013).
One of the lysosomal peptidases, namely cathepsin B, was shown
to degrade Aβ and its insufficient expression or inactivation
caused by its endogenous inhibitor cystatin C (CysC) could lead
to Aβ accumulation (Wang et al., 2012). Deficit of another lyso-
somal enzyme, sialidase NEU1, also leads to accumulation and
amyloidogenic processing of an oversialylated APP in lysosomes,
and extracellular release of Aβ peptides by excessive lysosomal
exocytosis (Annunziata et al., 2014). Reduced proteasome activity
was demonstrated to increase levels of intracellular and secreted
Aβ while accumulation of improperly degraded Aβ products
in the lysosomes causes lysosomal disruption and cell death
(Agholme et al., 2012). In turn, accumulation of Aβ oligomers
in cells causes proteasome inhibition leading to cell death (Tseng
et al., 2008). The oligomeric Aβ can be transmitted from one
neuron to another causing neurotoxicity and as such the drugs
which stop the spread of intracellular toxic Aβ aggregates may
also be useful for early prevention of developing AD pathol-
ogy (Agholme and Hallbeck, 2014). Both proteasomal and lyso-
somal degradation systems can be impaired during life by a
variety of pathological factors resulting in accumulation of Aβ
and predisposing to late-onset AD (Cuanalo-Contreras et al.,
2013).
Understanding the clearance mechanisms in the brain and
their regulation will help us to design therapies allowing the
brain to fight against undesirable accumulation of toxic protein
aggregates and to prolong its normal functioning. Deciphering
the mechanisms of regulation of the major ADEs, in particular
of NEP, lead us to a conclusion that there are some common
targets which can be treated simultaneously by the same com-
pounds modulating expression of several proteins involved in
amyloid clearance (for example NEP and TTR), and this can result
in design of a therapeutic strategy towards improved amyloid
clearance.
NEPRILYSIN (NEP) AND RELATED PEPTIDASES (NEP2, ECE-1, ECE-2)
One of the first ADEs in the brain to be identified was a cell-
surface, zinc metallopeptidase now known as NEP although this
enzyme was originally identified in the brush border membrane
of the kidney, where it is very abundant playing a role in degrading
circulating biologically active peptides (Kerr and Kenny, 1974). It
has subsequently been rediscovered in several guises in the body,
for example in B lymphocytes where it is known as the common
acute lymphoblastic leukaemia antigen (CALLA, CD10) (Letarte
et al., 1988), and in the brain where it was initially identified as
the peptidase turning off neuropeptide (enkephalins, substance
P) signaling (Roques et al., 1980; Matsas et al., 1983). NEP is also
the primary enzyme hydrolysing members of the atrial natriuretic
peptide family in the periphery.
NEP preferentially cleaves small peptides (up to about 50
amino acids) on the N-terminal side of hydrophobic residues and
hence the Aβ peptide is efficiently hydrolysed as was first shown
in vitro by Howell et al. (1995). Subsequently, the enzyme was
shown to be a major activity degrading both Aβ40 and Aβ42 in
the brain by examining Aβ degradation in NEP-deficient mice
and through the use of potent NEP inhibitors such as thiorphan
(Iwata et al., 2001; Shirotani et al., 2001). Viral gene delivery of
NEP to the brain of AD transgenic mice also was shown to reduce
amyloid pathology (Marr et al., 2003) and subsequent stud-
ies, including the application of a recombinant, brain-targeted
NEP (Spencer et al., 2014), have confirmed and extended these
observations on the critical nature of NEP to amyloid clearance
(Leissring et al., 2003). However, some caution is needed in
over-expressing human NEP as a therapeutic strategy since, in a
Drosophila model, while reducing transgenic Aβ42 levels this was
accompanied by axonal loss and a reduction in lifespan (Iijima-
Ando et al., 2008). Over-expression of a Drosophila homologue
of NEP also resulted in significant behavioral deficits (Bland et al.,
2009). These changes probably are a consequence of the substrate
promiscuity of NEP resulting in altered levels of neuropeptides. A
strategy to overcome this problem has involved identifying critical
catalytic residues and hence engineering the specificity of human
NEP to selectively enhance its Aβ-degrading capacity (Pope et al.,
2014; Webster et al., 2014). Functional profiling of several ADEs
in elderly and AD patients’ brains has provided additional support
for NEP as the major protease involved in Aβ degradation (Wang
et al., 2010).
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The human genome contains seven NEP-like genes, several
of which have now also been implicated in Aβ degradation.
The closest homologue to NEP, NEP2 (also known as mem-
brane metalloendopeptidase-like protein (MMELP)), can also
degrade Aβ40 and Aβ42 in vitro and in vivo and is recognized
as an important ADE and hence possible therapeutic target
(Hafez et al., 2011). However, there are significant substrate
and inhibitor specificity differences between rodent and human
NEP2 so some caution is needed in extrapolating data between
species (Whyteside and Turner, 2008). Unlike NEP, NEP2 exists in
alternatively spliced forms with differing subcellular distributions
but little is known of factors affecting NEP2 location or expres-
sion levels. Both NEP and NEP2 expression are altered in mild
cognitive impairment (MCI) subjects relative to non-impaired
subjects in AD-susceptible regions (Huang et al., 2012). NEP2
enzymic activity was decreased in both MCI and AD and was
positively associated with cognitive functions which suggested
that NEP2 may serve as a preclinical biomarker for AD (Huang
et al., 2012).
Two other NEP-like gene products that act as ADEs are the
endothelin converting enzymes (ECE-1 and ECE-2). ECE-1 is
mainly located in vascular endothelial cells where its principal role
is to act as a biosynthetic enzyme in the formation of the vasocon-
strictor peptide endothelin-1 from its precursor proendothelin-
1. ECE-1 may also metabolize some other circulating peptides,
e.g., bradykinin (Hoang and Turner, 1997). However, significant
levels of ECE-1 are present in the CNS (Barnes and Turner, 1997)
being involved in brain endothelin synthesis. It also plays a role in
endosomal neuropeptide metabolism regulating peptide receptor
recycling (Cottrell et al., 2009). Like NEP, ECE-1 can degrade Aβ
in vitro, and in vivo transgenic studies have implicated the enzyme
in physiological Aβ metabolism (Eckman and Eckman, 2005).
The much less studied homologue ECE-2, originally identified
by Emoto and Yanagisawa (1995) is also an excellent candidate
ADE being mainly brain located. ECE-2 levels are reported to be
increased in AD and it is up-regulated by Aβ itself (Palmer et al.,
2009). ECE-2, which has an acidic pH optimum, is localized in
secretory compartments and appears to be involved in protein
processing events (Mzhavia et al., 2003), including some opioid
peptides and thereby regulating opioid receptor activity (Gupta
et al., 2014). Increased concentrations of both Aβ1-40 and Aβ1-
42 are found in the brains of ECE-2 knockout mice (Eckman
et al., 2006). Recently using SH-SY5Y cells overexpressing wild-
type APP and pharmacological inhibition of endogenous ECE
activity it was shown that ECE-1 and ECE-2 participate in the
degradation of distinct pools of Aβ, one destined for secretion and
the other being produced and degraded within the endosomal-
autophagic-lysosomal pathways (Pacheco-Quinto and Eckman,
2013). Although ECE-1 regulates both pools of Aβ, ECE-2 reg-
ulates mainly the intracellular pool of the peptide, in particular
in the autophagic vesicles, suggesting that therapeutic targeting
of these enzymes might have different outcomes since it will
affect different pools of Aβ (Leissring and Turner, 2013; Pacheco-
Quinto and Eckman, 2013).
Consistent with the observations that AD patients have
reduced cerebral blood flow preceding onset of dementia, Palmer
and colleagues have been able to link these changes with
Aβ-induced cerebral vasoconstriction increasing ECE-1 levels and
hence ET-1 in a free radical-mediated process (Palmer et al.,
2009, 2012, 2013). Modulating ECE-1 levels therefore could have
opposing neuroprotective and neurotoxic effects through effects
on both Aβ and ET-1 levels.
INSULIN-DEGRADING ENZYME (INSULYSIN, IDE)
Another principal ADE, and the first to be identified (Kurochkin
and Goto, 1994), is the IDE (insulysin). This is a zinc peptidase
but structurally and mechanistically distinct from the NEP family
and also showing distinct cellular and subcellular localization. A
very diverse range of studies, from in vitro and cell-based studies
through to animal models now support an involvement of IDE in
amyloid clearance mechanisms (for review see Fernández-Gamba
et al., 2009; Nalivaeva et al., 2012a). Amyloid peptides associated
with British and Danish familial dementia were found among
the specific IDE substrates (Morelli et al., 2005). As its name
suggests, IDE was originally described as an enzyme implicated
in insulin metabolism and therefore of potential significance in
diabetes mellitus providing one of a number of links between
diabetes and AD (Yang and Song, 2013; Haque and Nazir, 2014).
Recently it was shown that IDE inhibitors might represent a
new therapeutic strategy to treat type-2 diabetes (Maianti et al.,
2014).
IDE has important substrates other than insulin and Aβ. In
particular, IDE is involved in elimination of oxidized proteins
in peroxisomes (Morita et al., 2000). It is also the principal
proteinase degrading cytosolic APP intracellular domain (AICD)
(Edbauer et al., 2002). Another physiological substrate for IDE
is somatostatin, a neuropeptide that declines in aging and AD,
which is also able to bind to and enhance IDE activity towards
Aβ through an allosteric action (Ciaccio et al., 2009) and to
upregulate NEP expression (Saito et al., 2005). Although it is
primarily located in the cytosol, IDE is found in lesser amounts in
mitochondria where Aβ can also be found (Leissring et al., 2004).
Surprisingly, given that it lacks any known secretory signal, a small
but significant proportion of IDE is secreted from cells through
an unconventional protein secretion pathway (Zhao et al., 2009).
This secreted IDE is functional in extracellular Aβ degradation
and it appears to be routed via detergent-resistant membrane
complexes into exosomes for secretion, along with Aβ (Bulloj
et al., 2010).
The recent development of novel IDE activators and inhibitors
(Cabrol et al., 2009; Leissring et al., 2010; Abdul-Hay et al., 2013;
Maianti et al., 2014) combined with detailed structural studies
of the enzyme (Im et al., 2007) should aid in unraveling the
importance of IDE in amyloid metabolism and pathology, and as
a therapeutic target.
OTHER ADEs
A wide and diverse variety of other proteases of all main cat-
alytic classes have been suggested as potential ADEs and their
involvement in these processes has been reviewed elsewhere
(e.g., Nalivaeva et al., 2012a) and will not be covered in detail
here. These include some metallopeptidases (matrix metallopro-
teinases, glutamate carboxypeptidase II), serine proteases (plas-
min, acylpeptide hydrolase), cysteine proteases (cathepsin B)
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and the aspartic protease, BACE-2. The latter enzyme was
a particularly efficient ADE and able to degrade intracellular
Aβ (Abdul-Hay et al., 2012). Although angiotensin-converting
enzyme (ACE) was shown to be capable of Aβ cleavage (Hemming
and Selkoe, 2005) mostly acting as a carboxydipeptidase and
converting the more hydrophobic and toxic Aβ42 to Aβ40 (Zou
et al., 2007), its role in AD pathology is still not clear. A
recent study employing ACE overexpression in myelomonocytes
of APP(SWE)/PS1(∆E9) mice has convincingly demonstrated
the protective effect of ACE against cognitive decline but this
effect was most likely linked to an enhanced immune response,
coupled with increased myelomonocytic expression of catalyti-
cally active ACE (Bernstein et al., 2014). The ACE homologue,
ACE2, is a metallo-carboxypeptidase that converts Aβ43 to Aβ42
which can then be converted to Aβ40 by ACE (Liu et al.,
2014). Hence, maintaining brain ACE2 and ACE activities might
be important for preventing accumulation of more toxic Aβ
species.
DEFICIT OF ADEs UNDER PATHOLOGICAL CONDITIONS AND
AGEING
Ageing is considered as one of the major risk factors of late-
onset AD. Although literature data demonstrate a link between
AD pathology and the level of activity and expression of ADEs
in the brain there are some contradictions in the reported results
which might be caused by the source of the brain material
used, its maintenance before the analysis and also by the tech-
niques applied. Reduced NEP mRNA levels were reported in the
hippocampus and temporal gyrus of AD patients suggesting a
relationship between NEP activity and deficient degradation of
Aβ peptide leading to high number of senile plaques in these brain
areas (Yasojima et al., 2001). Similarly, reduced IDE levels were
reported in the hippocampus of AD patients bearing the APOEε4
allele (Cook et al., 2003). It was also shown that NEP and IDE
decline with age in human cortex and hippocampus and IDE is
more oxidized in the hippocampus of AD patients compared to
the cerebellum (Caccamo et al., 2005). Reduced activity of NEP
was also observed in the cerebrospinal fluid (CSF) of demented
patients with Lewy body pathology (Maetzler et al., 2010). On
the contrary there were no differences reported in NEP mRNA
levels in the temporal lobe of AD patients compared to age-
matched controls although the authors observed some changes
in the somatostatin system suggesting that this might impair
NEP regulation and cause a deficit of its activity leading to Aβ
accumulation (Gahete et al., 2010). Moreover, postmortem anal-
ysis of NEP activity by immunocapture-based fluorogenic assays
revealed an increase in NEP and IDE activity in the frontal cortex
from subjects of different ages and with different pathological
stages of AD progression (Miners et al., 2009). Based on these
observations the authors suggested that reduction in NEP and
IDE activity is not the primary cause of Aβ accumulation in AD,
but rather a late-stage phenomenon secondary to neurodegener-
ation. Our own data on rat brain demonstrate that NEP mRNA
and protein levels in the cortex and hippocampus significantly
decline with age being the highest in the first month of animal
life when development of the nervous system and its neuronal
networks is the most active. On the contrary, in the striatum, NEP
expression remained at a relatively high level during advanced age
(Nalivaeva et al., 2004, 2012c). Regarding the human brain there
are no systematic data showing the dynamics of NEP or other
ADEs expression in various brain structures with aging and in the
cases of development of MCI and AD which would significantly
contribute to our understanding of the role of these enzymes in
normal human brain development, functioning and pathogene-
sis. The recently developed McGill-Thyl-APP transgenic mouse
model of AD demonstrates significant down-regulation of IDE
at the preclinical early stage of AD pathology which could make
it a valuable model for exploring mechanisms to restore enzyme
activity (Ferretti et al., 2011).
Among the factors which predispose to the development of
late-onset AD are hypoxia, ischaemia, stroke, stress, diabetes,
trauma and neuroinflammation. All of them were shown to affect
amyloid metabolism and to some extent the levels of expression
and activity of ADEs. The analysis of ischaemically damaged
brains of patients demonstrated that ischaemic episodes trigger
dysregulation of expression of a number of AD-related genes
(Pluta et al., 2013). Monitoring plaque formation in real time
in a mouse model has revealed that stroke can trigger acceler-
ated amyloid deposition, most likely through interference with
amyloid clearance pathways along interstitial fluid drainage routes
(Garcia-Alloza et al., 2011). Our studies have demonstrated that
experimental four-vessel occlusion ischaemia in rats resulted in
down-regulation of NEP and ECE-1 as well as up-regulation of
APP and BACE both in the cortex and hippocampus (Nalivaeva
et al., 2004, 2005). On the contrary, levels of IDE were up-
regulated after ischaemia both at the mRNA and protein levels
(unpublished data). These findings strongly correlate with the
changes in NEP and IDE expression patterns observed in rat
thalamus after focal cerebral ischaemia (Hiltunen et al., 2009).
Up-regulation of IDE mRNA was also observed in a perma-
nent two-vessel occlusion ischaemia model in rats which was
attenuated by administration of a natural product (Choto-san)
widely used in Japan for treatment of vascular dementia (Hayashi
et al., 2005). The apparent anti-dementia effects of this medicine
have been shown to be due to its anti-hypertensive, free radical
scavenging, and anti-excitotoxic effects (Watanabe et al., 2003).
However, these authors used whole brain mRNA extracts which
diminishes the value of their results in relation to the brain
areas affected by AD. A different pattern of IDE regulation under
ischaemic conditions was also observed in wild-type mice and
mice with a deficient Toll-receptor system suggesting that the
Toll/interleukin-1 receptor domain-containing adaptor inducing
interferon-β (TRIF) pathway regulates IDE expression (Famakin
et al., 2014).
Cerebrovascular pathology and ischaemia are the major fac-
tors leading to insufficient oxygen supply to the brain causing
metabolic changes in neuronal cells predisposing to neurode-
generation and AD (Bazan et al., 2002). Previously we have
demonstrated that hypoxia in neuroblastoma NB7 cells and rat
primary cortical neurones lead to down-regulation of mRNA
and protein levels of NEP as well as its enzyme activity (Fisk
et al., 2007). We have also observed around 30% decrease in
expression of ECE-1 under hypoxic conditions at the protein level,
although at the level of ECE-1 mRNA there were no statistically
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significant changes (Fisk et al., 2006). These data correlate with
reduced NEP activity in the cortex and hippocampus of rats
subjected to prenatal hypoxia (Nalivaeva et al., 2012b; Wang et al.,
2014b).
In the AD brain decreased levels of NEP expression were also
observed along the vasculature suggesting its role in the devel-
opment of cerebral amyloid angiopathy (CAA) in AD patients
(Carpentier et al., 2002; Miners et al., 2006). Assessing the pro-
tective role of NEP in the vasculature it was shown that NEP can
rescue cerebrovascular smooth muscle cells against Aβ-induced
cell death and prevent complications of CAA (Miners et al.,
2011). Along with the age-related decrease of NEP expression
observed in neuronal cells, Apelt and colleagues have reported
up-regulation of this enzyme in reactive astrocytes surrounding
amyloid plaques in AD transgenic mice (Apelt et al., 2003) which
is considered to be a compensatory reaction of a specific set of
brain cells possessing a protective function. These observations
stimulated a cascade of studies on possible mechanisms of NEP
up-regulation as a strategy for AD treatment through stimu-
lating clearance of Aβ peptides and/or their various aggregated
forms.
PHARMACOLOGICAL AND EPIGENETIC REGULATION OF ADE
GENES
Various strategies have been suggested to increase expression
and activity of ADEs, in particular of NEP, in the brain areas
vulnerable to accumulation of amyloid burden and neuronal cell
death. Developing targeted gene delivery techniques several viral
vectors have been utilized including Sindbis viral (Hama et al.,
2001), lentiviral (Marr et al., 2003) or adenoviral (Iwata et al.,
2013) delivery which proved to be effective in reducing amyloid
burden in treated brain areas. The last approach, which allowed
global neuronal gene expression throughout the brains, utilized
peripheral intravascular administration of the gene-targeted vec-
tor. Refining the methods of NEP delivery from the periphery
to the brain, intra-peritoneal injections of a lentiviral vector
expressing NEP fused with the ApoB transport domain was found
to be effective in reducing levels of Aβ and the number of plaques
in the brain of AD transgenic mice (Spencer et al., 2011). The
optimal timing of NEP over-expression has also been examined
suggesting that earlier up-regulation of NEP was more beneficial
in alleviating AD symptoms in a mouse model (El-Amouri et al.,
2008). In line with the attempts at transgenic over-expression of
NEP in neuronal cells it was also shown that increased IDE expres-
sion can lead to reduced brain Aβ and delay of AD pathology
(Leissring et al., 2003).
Delivery of NEP to peripheral tissues has also proved effective
in reducing the deposits of islet amyloid polypeptide (IAPP)
which contribute to type 2 diabetes. Thus, adenoviral delivery
of NEP to the pancreas reduced amyloid deposits and cell death
in the islets (Zraika et al., 2010). However, in this case, NEP did
not act via degradation of IAPP but appeared to act by inhibiting
the amyloid fibril formation through protein-protein interactions
involving the enzyme active site, rather than by hydrolysing the
peptide.
Because brain and plasma Aβ are considered to be in
an equilibrium through transport mechanisms (Deane et al.,
2004), Hersh and colleagues have investigated whether enhancing
peripheral degradation of Aβ by NEP could reduce brain lev-
els and associated pathology. Their reports suggest that in AD
transgenic mice over-expression of NEP in erythrocytes or leuko-
cytes leads to a reduced Aβ burden in the brain (Liu et al.,
2007; Guan et al., 2009). Similar results were observed when
NEP was over-expressed in skeletal muscle (Liu et al., 2009).
An alternative strategy of expressing a secreted, soluble form
of NEP in plasma through an adenovirus construct was also
effective in clearing brain Aβ yet did not affect plasma levels
of other peptide substrates of NEP such as bradykinin or sub-
stance P (Liu et al., 2010). Expressing NEP in plasma might
provide a simple system allowing the monitoring of its long-
term activity, and this approach has recently been re-examined
by using albumin-fused NEP with extended half-life (Henderson
et al., 2014). This study demonstrated that although NEP highly
effectively degraded Aβ in the periphery it did not alter brain
or CSF Aβ levels, suggesting that the peripheral sink hypothesis
might not be valid and supporting earlier observations of Walker
et al. (2013). However, the experiments in both studies have been
performed in transgenic mice and non-human primates and the
validity of these conclusions for human pathology still needs to be
assessed.
Apart from gene-targeted manipulations of the expression
of ADEs, a number of studies have aimed at pharmacological
up-regulation of these enzymes and one of the earlier works
reported that retinoic acid which induces cell differentiation
was able to increase IDE expression and activity (Melino et al.,
1996). Aiming at NEP regulation, Saido et al. have put forward
a hypothesis that elevated levels of neuropeptide substrates of
NEP could themselves up-regulate NEP via a feedback control
mechanism. They hence screened a wide range of NEP substrates
demonstrating that, of those tested, only somatostatin was capable
of up-regulating NEP expression in primary neuronal cells in
a mechanism possibly mediated through somatostatin receptor
sub-types 2 or 4 (Saito et al., 2005). Utilization of somatostatin
agonists as a possible therapeutic strategy for prevention of AD
was recently reinforced by Saido (2013). An alternative strategy
for pharmacological up-regulation of NEP was reported in a
study analyzing the effects of a selective peroxisome proliferator
activated receptor-δ (PPARδ) agonist, GW742, which activated
the NEP promoter driving luciferase expression in transfected
HEK293 cells (Kalinin et al., 2009). This treatment reduced plaque
burden in 5xFAD mice which harbor 3 mutations in APP and
2 mutations in PS1 not only by NEP activation but also by
increased expression of IDE. IDE expression was also shown to
be up-regulated by norepinephrine via the β2 adrenergic receptor
resulting in activation of Aβ uptake and degradation by microglia
(Kong et al., 2010). Another brain metabolite, namely kynurenic
acid, was reported to regulate NEP mRNA and protein levels
in SH-SY5Y cells and mouse cortical neurones and to have a
protective effect on cell survival which was thiorphan-dependent
(Klein et al., 2013).
Although reports on the effect of the protein kinase C inhibitor
and anticancer drug Gleevec on NEP up-regulation were to
some extent contradictory (Eisele et al., 2007; Vázquez et al.,
2009), our recent data confirmed that Gleevec can increase NEP
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expression in cell models (Kerridge et al., 2014). On the other
hand, selective activation of protein kinase Cε (e.g., with bryo-
statin) was also shown to reduce Aβ levels through enhanc-
ing NEP expression and cell-surface activity (Lim and Alkon,
2014).
Analyzing the effects of such common drugs as statins on
the status of ADEs in the brain Tamboli et al. (2010) demon-
strated a potential positive effect of lovastatin and itraconazole on
Aβ degradation and clearance via increased exosome-associated
secretion of IDE by microglia. Lovastatin injections also stimu-
lated release of IDE in the circulation of mice. However, in another
study using a transgenic mouse model the authors failed to
observe any effects of simvastatin on NEP activity (Papadopoulos
et al., 2014). Among lipid species, docosahexaenoic acid (DHA)
was also shown to up-regulate IDE while palmitic acid had an
opposite effect (Du et al., 2010).
A variety of other strategies to enhance activity levels of
NEP have also been examined including epigenetic approaches
(see below), as well as natural products that can upregulate the
enzyme (green tea catechins, curcumin, flavones, etc.) (Melzig
and Janka, 2003; Ayoub and Melzig, 2006; Kiss et al., 2006;
Deng et al., 2014; Fujiwara et al., 2014). Green tea catechins
were shown to be preventive in AD animal models via up-
regulation of NEP (Lim et al., 2013). Human adipose tissue-
derived mesenchymal stem cells have been shown to secrete
exosomes carrying functionally active NEP (Katsuda et al., 2013)
and neuronally differentiated human umbilical cord mesenchy-
mal stem cells transplanted into APP transgenic mice reduced
Aβ levels and enhanced both NEP and IDE levels, as well as
cognitive function, raising the prospect of future cell therapy for
AD (Yang et al., 2013). Recently a non-invasive physiologically
relevant way to up-regulate NEP expression was examined in an
animal model demonstrating that enriched environment has a
protective effect against Aβ accumulation and age-related cogni-
tive decline (Mainardi et al., 2014) supporting earlier observations
that brain NEP is upregulated under such conditions (Lazarov
et al., 2005).
ROLE OF APP IN REGULATION OF ADE GENES
Apart from Aβ and N-terminal products released from APP
during its proteolytic processing via γ-secretase cleavage (see
Figure 1) there are several C-terminal fragments or AICDs. Their
formation is similar to the cleavage of the Notch protein, which
liberates an intracellular domain (NICD) capable of translocating
to the nucleus and regulating gene transcription (Schroeter et al.,
1998). AICD was also proposed to act as a transcriptional reg-
ulator (Passer et al., 2000) and by using luciferase reporter-based
assays, it was shown that AICD can form a transcriptionally active
complex with the nuclear adaptor (and AICD stabilizing protein)
Fe65 and the histone acetyltransferase Tip60 (Cao and Südhof,
2001).
Since that first report of the transcriptional activity of the C-
terminal fragment released from APP cleavage by γ-secretase, the
transcriptional activity of AICD has been intensively studied (for
review, see Beckett et al., 2012; Konietzko, 2012; Pardossi-Piquard
and Checler, 2012) and the number of genes suggested to be
regulated by AICD is steadily increasing. However, to date, only
the NEP gene has unequivocally been shown to be functionally
regulated by AICD (Pardossi-Piquard et al., 2005; Belyaev et al.,
2009). Moreover, it has been established that only the AICD
derived from the neuronal APP695 but not from APP751 or
APP770 in a β-secretase-dependent pathway is accumulated in the
nucleus and up-regulates NEP expression (Belyaev et al., 2010).
Mechanistically at the transcriptional level up-regulation of NEP
expression by AICD involves the binding of AICD to the MED12
unit of the Mediator RNA polymerase II complex (Xu et al., 2011).
This finding provides a missing functional link between nuclear
AICD binding and its transcriptional activity (Turner et al., 2011)
and allowed the validation of additional AICD-dependent genes
such as aquaporin-1, MICAL2 and Fibronectin-1 (Xu et al.,
2011).
Using two neuroblastoma cell lines, SH-SY5Y characterized
by very low levels of NEP expression, and NB7 which produce
a significant amount of NEP we have demonstrated that in the
case of low NEP-expressing cells the NEP promoter is occupied
by the histone-deacetylase HDAC1 while in NB7 cells by AICD.
Treating SH-SY5Y cells with HDAC inhibitors trichostatin A or
valproic acid (VA) we were able to up-regulate levels of NEP
expression (Belyaev et al., 2009). VA is chiefly known as a highly
successful and widely used antiepileptic drug but its efficacy in
neurodegenerative disease has been much less studied (Nalivaeva
et al., 2009), although there are several recent reports of its ben-
eficial effects in reducing amyloid accumulation and improving
cognitive function in AD mice (Qing et al., 2008), and amyloid
clearance via microglial phagocytosis (Smith et al., 2010). VA also
up-regulates NEP in the cortex and hippocampus and restores
memory deficit caused by hypoxia in rats (Nalivaeva et al., 2012b)
and in transgenic mice subjected to prenatal hypoxia (Wang et al.,
2014b). The potential of VA and other HDAC inhibitors in the
treatment of neurodegeneration has been further strengthened
by the recent report that inhibitors of class 1 HDACs reverse
contextual memory deficits in an AD mouse model (Kilgore et al.,
2010), a process termed “epigenetic memory rescue”. Others have
also supported the potential value of VA in AD as a mechanism to
“untie tangles” coupled with its ability to induce neurogenesis of
neural progenitor/stem cells both in vitro and in vivo via multiple
signaling pathways including up-regulation of the nerve growth
factor gene (Nalivaeva et al., 2009; Tariot and Aisen, 2009; Noh
and Seo, 2014). There is clearly scope for more robust clinical
trials on selective HDAC inhibitors in AD, particularly at earlier
stages in disease progression. Given the prolonged and successful
use of VA clinically in the treatment of epilepsy, there are grounds
for more detailed retrospective epidemiological surveys in rela-
tion to AD incidence in valproate-users and control patients.
Since AICD is rapidly degraded within the cytoplasm, in par-
ticular by IDE (Cupers et al., 2001; Edbauer et al., 2002) treatment
of cells with IDE inhibitors or an alkalising agent such as NH4Cl
(Vingtdeux et al., 2007) was proved to be able to stabilize AICD
and its nuclear pool resulting in increased NEP expression and
activity and reduced Aβ levels in the cell medium (Kerridge et al.,
2014). Apart from degradation, Aβ-sequestration by clearance
proteins also precludes Aβ oligomerization and plaque formation.
A major Aβ-binding protein in the brain is TTR (Du et al., 2012),
which suppresses Aβ aggregation, facilitates its clearance and
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prevents Aβ-induced cytotoxicity (Tsuzuki et al., 2000; Brouillette
et al., 2012; Li et al., 2013). Increased levels of TTR have been
observed in transgenic mice over-expressing mutant APP (Stein
and Johnson, 2002) but whether this effect was mediated by AICD
and is APP isoform-dependent has not been investigated. Recently
we have reported that TTR is regulated by AICD and HDAC
similarly to NEP (Kerridge et al., 2014).
Among therapeutic strategies to improve Aβ clearance in the
brain special attention has been paid to a recently reported
effect of a retinoid X receptors (RXR) agonist bexarotene also
used as an anti-cancer drug in patients with cutaneous T-cell
lymphoma (Cramer et al., 2012). Oral administration of this drug
to mice with AD pathology caused a rapid enhanced clearance
of soluble Aβ which resulted within a few days in a reduced
amyloid plaque area and in rapid reversal of cognitive, social,
and olfactory deficits. Such fast clearance of Aβ in the brain
had an ApoE-dependent character although there might be other
mechanisms involved and more studies are need to evaluate the
clinical value of this drug in AD (LaFerla, 2012; Strittmatter,
2012). Bexarotene also blocks calcium-permeable ion channels
formed by Aβ peptides by competing with a cholesterol-binding
domain in Aβ (Fantini et al., 2014).
FUTURE PERSPECTIVES
As suggested above, epigenetic regulation of AD-related genes is
now considered a plausible strategy for designing new therapies
against late-onset AD. For example, simultaneous up-regulation
of NEP and TTR gene expression by Gleevec might provide
a platform for designing a strategy towards enhancement of
amyloid clearance in the ageing brain via different mechanisms.
Epigenetic regulation of the clusterin gene expression can also
play an important role in AD pathogenesis via inhibition of Aβ
aggregation (Li et al., 2014).
Although several compounds have been discarded on the
grounds of limited clinical efficacy, all major clearance-related
approaches still hold promise. Among some drug candidates
advanced to Phase III trials are anti-Aβ antibodies, metal com-
plexing agents, ginseng extracts, and intravenous immunoglobu-
lins (Kurz and Perneczky, 2011). Recent data, including our own
reports, strongly support the possibility that clearance-related
strategies have the potential for protecting neuronal cells and cog-
nitive functions via reducing the levels of soluble and particularly
toxic Aβ species in the brain.
With all the advances in our knowledge of amyloid metabolism
and the increase in number of ADEs that have been identified
in multiple cell types and brain regions acting co-ordinately to
regulate Aβ levels, it is still very surprising that relatively little
is known about the precise physiological role of this peptide.
Considering that in the cells there is a very well defined and tuned
mechanism of Aβ production and removal one can expect that
this peptide might have an important role which, when disturbed,
can lead to the disease. New functions of Aβ continue to emerge,
for example, even as a regulator of gene transcription (Maloney
and Lahiri, 2011; Barucker et al., 2014). Recent strategies in drug
design could be more successful if more effort had been put into
the study of normal physiology of this peptide and its precursor
protein APP (Nalivaeva and Turner, 2013).
Taking into account that AD pathology develops over many
years, early manipulation of ADEs might be essential to pre-
vent amyloid deposition and disease progression. However, the
efficacy of any preventive treatment will be strongly driven by
the development of early diagnosis and pre-clinical markers of
AD. Recent systematic studies of blood protein biomarkers have
shown potential in prediction and monitoring the progression of
AD (Kiddle et al., 2014; Sattlecker et al., 2014). Levels of expres-
sion and activity of ADEs, e.g., in blood serum, might be of some
importance but more systematic analysis is required to prove any
correlation between these enzymes and disease progression. Since
AD is a multifactorial disease a single focus for diagnostics or
treatment is unlikely to be productive so a combination therapy
targeting various links in the chain of pathological events leading
to AD is likely to be optimal. Combining the efforts in gaining new
knowledge about various protective mechanisms and the ways of
their enhancement is the key to success.
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